Literature DB >> 33574791

Neurocognitive Predictors of Treatment Outcomes in Cognitive Processing Therapy for Post-traumatic Stress Disorder: Study Protocol.

David P Cenkner1, Anu Asnaani2, Christina DiChiara1, Gerlinde C Harb1, Kevin G Lynch1,3, Jennifer Greene1, J Cobb Scott1,3.   

Abstract

BACKGROUND: Post-traumatic stress disorder (PTSD) is a prevalent, debilitating, and costly psychiatric disorder. Evidenced-based psychotherapies, including Cognitive Processing Therapy (CPT), are effective in treating PTSD, although a fair proportion of individuals show limited benefit from such treatments. CPT requires cognitive demands such as encoding, recalling, and implementing new information, resulting in behavioral change that may improve PTSD symptoms. Individuals with PTSD show worse cognitive functioning than those without PTSD, particularly in acquisition of verbal memory. Therefore, memory dysfunction may limit treatment gains in CPT in some individuals with PTSD. METHODS AND ANALYSIS: Here, we present a protocol describing the Cognition and PsychoTherapy in PTSD (CPTPTSD) study, a prospective, observational study examining how cognitive functioning affects treatment response in CPT for PTSD (NCT# 03641924). The study aims to recruit 105 outpatient veterans with PTSD between the ages of 18 and 70 years. Prior to beginning 12 sessions of CPT, Veteran participants will have standardized assessments of mood and functioning and complete a comprehensive neurocognitive battery assessing episodic learning, attention and speed of processing, language ability, executive control, and emotional functioning. This study aims to fill gaps in the current literature by: (1) examining the specificity of memory effects on treatment response; (2) exploring how baseline cognitive functioning impacts functional outcomes; and (3) examining potential mechanisms, such as memory for treatment content, that might explain the effects of baseline memory functioning on PTSD symptom trajectory. DISCUSSION: If successful, this research could identify clinically relevant neurocognitive mechanisms that may impact PTSD psychotherapy and guide the development of individualized treatments for PTSD.
Copyright © 2021 Cenkner, Asnaani, DiChiara, Harb, Lynch, Greene and Scott.

Entities:  

Keywords:  PTSD—post-traumatic stress disorder; cognitive functioning; memory; psychotherapy mechanisms; psychotherapy research

Year:  2021        PMID: 33574791      PMCID: PMC7870481          DOI: 10.3389/fpsyg.2021.625669

Source DB:  PubMed          Journal:  Front Psychol        ISSN: 1664-1078


  56 in total

1.  The Computerized Neurocognitive Battery: Validation, aging effects, and heritability across cognitive domains.

Authors:  Suzanne C Swagerman; Eco J C de Geus; Kees-Jan Kan; Elsje van Bergen; Harold A Nieuwboer; Marinka M G Koenis; Hilleke E Hulshoff Pol; Raquel E Gur; Ruben C Gur; Dorret I Boomsma
Journal:  Neuropsychology       Date:  2016-01       Impact factor: 3.295

2.  Deployment risk and resilience inventory-2 (DRRI-2): an updated tool for assessing psychosocial risk and resilience factors among service members and veterans.

Authors:  Dawne Vogt; Brian N Smith; Lynda A King; Daniel W King; Jeffrey Knight; Jennifer J Vasterling
Journal:  J Trauma Stress       Date:  2013-12

3.  Dissemination of methods and results from the veterans health study: final comments and implications for future monitoring strategies within and outside the veterans healthcare system.

Authors:  Lewis E Kazis; Alfredo Selim; William Rogers; Xinhua S Ren; Austin Lee; Donald R Miller
Journal:  J Ambul Care Manage       Date:  2006 Oct-Dec

4.  Deconstructing processing speed deficits in schizophrenia: application of a parametric digit symbol coding test.

Authors:  Peter Bachman; Abraham Reichenberg; Patrick Rice; Mary Woolsey; Olga Chaves; David Martinez; Natalie Maples; Dawn I Velligan; David C Glahn
Journal:  Schizophr Res       Date:  2010-03-02       Impact factor: 4.939

5.  Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons.

Authors:  Jennifer J Vasterling; Lisa M Duke; Kevin Brailey; Joseph I Constans; Albert N Allain; Patricia B Sutker
Journal:  Neuropsychology       Date:  2002-01       Impact factor: 3.295

6.  Military Sexual Trauma and Co-occurring Posttraumatic Stress Disorder, Depressive Disorders, and Substance Use Disorders among Returning Afghanistan and Iraq Veterans.

Authors:  Amanda K Gilmore; Emily Brignone; Janelle M Painter; Keren Lehavot; Jamison Fargo; Ying Suo; Tracy Simpson; Marjorie E Carter; Rebecca K Blais; Adi V Gundlapalli
Journal:  Womens Health Issues       Date:  2016-08-12

7.  Substance abuse treatment outcomes for cognitively impaired and intact outpatients.

Authors:  Gordon Teichner; Michael D Horner; John C Roitzsch; Janice Herron; Angelica Thevos
Journal:  Addict Behav       Date:  2002 Sep-Oct       Impact factor: 3.913

8.  Development of abbreviated eight-item form of the Penn Verbal Reasoning Test.

Authors:  Warren B Bilker; Michael R Wierzbicki; Colleen M Brensinger; Raquel E Gur; Ruben C Gur
Journal:  Assessment       Date:  2014-02-26

9.  A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation.

Authors:  Ruben C Gur; Jan Richard; Paul Hughett; Monica E Calkins; Larry Macy; Warren B Bilker; Colleen Brensinger; Raquel E Gur
Journal:  J Neurosci Methods       Date:  2009-11-27       Impact factor: 2.390

10.  Chronicity of posttraumatic stress disorder and risk of disability in older persons.

Authors:  Amy L Byers; Kenneth E Covinsky; Thomas C Neylan; Kristine Yaffe
Journal:  JAMA Psychiatry       Date:  2014-05       Impact factor: 21.596

View more
  1 in total

1.  Sotalol Treatment may Interfere With Retrieval, Expression, and/or Reconsolidation Processes Thus Disrupting Traumatic Memories in a Post-Traumatic Stress Disorder Mice Model.

Authors:  Raquel Martinho; Rafaela Seixas; Márcia Azevedo; Ana Oliveira; Paula Serrão; Mónica Moreira-Rodrigues
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.